Introgen Technical Services Signs New Contract Manufacturing Agreements
Contracts Totaling over $1 Million to Produce Novel Biologic Therapeutics for Two New Customers; Expanded Relationship with Long-Term Customer
HOUSTON--(BUSINESS WIRE)--Introgen Technical Services, Inc. (ITS) today announced that the company has expanded its contract manufacturing and service business by signing manufacturing agreements to produce biological materials for two key new customers: Advantagene, Inc. and the H. Lee Moffitt Cancer Center. Additionally, ITS has expanded its ongoing collaborative relationship with Oncolys BioPharma, Inc. through completion of additional GMP production services for that company. Aggregate proceeds to ITS from these contracts total more that $1 million. Under the terms of these new agreements, ITS will produce GMP-grade biologics for use in oncology applications including:
"The signing and execution of these new manufacturing agreements provide tremendous validation for ITS and the manufacturing services that we offer to leading companies and academic institutions in the area of drug development and research," said David Enloe, ITS president and chief executive officer. "We are pleased to add Advantagene and the H. Lee Moffitt Cancer Center to our growing list of manufacturing customers and look forward to providing them with the top-quality products and unmatched service that our existing customers, such as Oncolys BioPharma, have come to expect from ITS."
"The facilities, technical expertise and quality project management required for the manufacture of a product such as Telomelysin are significant and that is the primary reason that we selected ITS as our manufacturing partner," said Yasuo Urata, president and CEO of Oncolys BioPharma. "ITS has demonstrated an exceptional track record of successfully producing complex biologics for Oncolys BioPharma and we are excited to expand our relationship with them."
ABOUT INTROGEN TECHNICAL SERVICES (ITS)
ITS provides its customers with flexible, disposable technology-dependent, scalable Good Manufacturing Practices (GMP) production capabilities, including the skills needed to convert early stage, lab-grade production into robust and scalable therapeutic product classes, suitable for clinical studies and commercial use. ITS offers its clients access to its intellectual property portfolio, including patents, proprietary quality and validation systems, and broad GMP knowledge systems. ITS operates a GMP clean room facility which includes process development, scale-up, production and fill/finish capabilities, as well as QC labs. Through its parent company, ITS created the adenoviral reference material (ARM) that serves as the industry gold standard against which all other U.S. adenovirus-based materials are compared.
For more information about ITS, please visit www.its-gmp.com.